MicroRNAs in hereditary diffuse gastric cancer (Review)

Suárez‑Arriaga,Mayra‑Cecilia; Ribas‑Aparicio,Rosa‑María; Ruiz‑Tachiquín,Martha‑Eugenia

doi:10.3892/br.2016.706

MicroRNAs in hereditary diffuse gastric cancer (Review)

Authors:
- Mayra‑Cecilia Suárez‑Arriaga
- Rosa‑María Ribas‑Aparicio
- Martha‑Eugenia Ruiz‑Tachiquín
View Affiliations

Affiliations: Medical Research Unit in Human Genetics, Hospital of Pediatrics, National Medical Center XXI Century, Mexican Social Security Institute, Mexico City 06720, Mexico, Department of Microbiology, National School of Biological Sciences, National Polytechnic Institute, Mexico City 11340, Mexico
Published online on: June 24, 2016 https://doi.org/10.3892/br.2016.706
Pages: 151-154

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In 2012, gastric cancer (GC) was the third cause of mortality due to cancer in men and women. In Central and South America, high mortality rates have been reported. A total of 95% of tumors developed in the stomach are of epithelial origin; thus, these are denominated adenocarcinomas of the stomach. Diverse classification systems have been established, among which two types of GC based on histological type and growth pattern have been described as follows: Intestinal (IGC) and diffuse (DGC). Approximately 1‑3% of GC cases are associated with heredity. Hereditary‑DGC (HDGC), with 80% penetrance, is an autosomal‑type, dominant syndrome in which 40% of cases are carriers of diverse mutations of the CDH1 gene, which encodes for the cadherin protein. By contrast, microRNA are non‑encoded, single‑chain RNA molecules. These molecules regulate the majority of cellular functions at the post‑transcriptional level. However, analysis of these interactions by means of Systems Biology has allowed the understanding of complex and heterogeneous diseases, such as cancer. These molecules are ubiquitous; however, their expression can be specific in different tissues either temporarily or permanently, depending on the stage of the cell. Due to the participation of microRNA in the processes of cellular proliferation, cell cycle control, apoptosis, differentiation and metabolism, these have been indicated to have a role in the development of cancerous processes, finding specific patterns of expression in different neoplasms, including GC, in which the microRNA expression profile is different in samples of non‑cancerous versus cancerous tissues. A difference has been observed in the expression patterns of DGC and IGC. However, the role of microRNA in HDGC has not yet been established. The present study reviews the investigations that describe the participation of microRNA in the regulation of genes CDH1, RHOA, CTNNA1, INSR and TGF‑β in different neoplasms, such as HDGC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	INEGI: Estadísticas a propósito del Día Mundial contra el Cáncer. http://www.inegi.org.mx/saladeprensa/aproposito/2016/cancer2016_0.pdfAccessed. March 06–2016
3	Hu B, El Hajj N, Sittler S, Lammert N, Barnes R and Meloni-Ehrig A: Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 3:251–261. 2012.PubMed/NCBI
4	Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
5	Piazuelo MB, Epplein M and Correa P: Gastric cancer: An infectious disease. Infect Dis Clin North Am. 24:853–869, vii. 2010. View Article : Google Scholar : PubMed/NCBI
6	Tan RYC and Ngeow J: Hereditary diffuse gastric cancer: What the clinician should know. World J Gastrointest Oncol. 7:153–160. 2015. View Article : Google Scholar : PubMed/NCBI
7	Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, et al: International Gastric Cancer Linkage Consortium: Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 47:436–444. 2010. View Article : Google Scholar : PubMed/NCBI
8	Corso G, Marrelli D, Pascale V, Vindigni C and Roviello F: Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: Metanalysis and systematic review of the literature. BMC Cancer. 12:82012. View Article : Google Scholar : PubMed/NCBI
9	van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, et al: Hereditary diffuse gastric cancer: Updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 52:361–374. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y, et al: Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 46:583–587. 2014. View Article : Google Scholar : PubMed/NCBI
11	Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 46:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
12	Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D, Kluin RJ, Hansford S, Hogervorst FB, Bosma AJ, Hofland I, et al: An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol. 229:621–629. 2013. View Article : Google Scholar : PubMed/NCBI
13	Gaston D, Hansford S, Oliveira C, Nightingale M, Pinheiro H, Macgillivray C, Kaurah P, Rideout AL, Steele P, Soares G, et al: Germline mutations in MAP3K6 are associated with familial gastric cancer. PLoS Genet. 10:e10046692014. View Article : Google Scholar : PubMed/NCBI
14	Donner I, Kiviluoto T, Ristimäki A, Aaltonen LA and Vahteristo P: Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer. Fam Cancer. 14:241–246. 2015. View Article : Google Scholar : PubMed/NCBI
15	Li X, Yue ZC, Zhang YY, Bai J, Meng XN, Geng JS and Fu SB: Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. J Clin Lab Anal. 22:164–171. 2008. View Article : Google Scholar : PubMed/NCBI
16	Prasasya RD, Tian D and Kreeger PK: Analysis of cancer signaling networks by systems biology to develop therapies. Semin Cancer Biol. 21:200–206. 2011. View Article : Google Scholar : PubMed/NCBI
17	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
18	Munker R and Calin GA: MicroRNA profiling in cancer. Clin Sci (Lond). 121:141–158. 2011. View Article : Google Scholar : PubMed/NCBI
19	Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
20	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
21	Jiang C, Chen X, Alattar M, Wei J and Liu H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
22	Shrestha S, Hsu SD, Huang WY, Huang HY, Chen W, Weng SL and Huang HD: A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 3:878–888. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
24	Song Y, Li J, Zhu Y, Dai Y, Zeng T, Liu L, Li J, Wang H, Qin Y, Zeng M, et al: MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget. 5:11669–11680. 2014. View Article : Google Scholar : PubMed/NCBI
25	Chen Y, Kingham K, Ford JM, Rosing J, Van Dam J, Jeffrey RB, Longacre TA, Chun N, Kurian A and Norton JA: A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol. 18:2594–2598. 2011. View Article : Google Scholar : PubMed/NCBI
26	Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, Li X and Wu M: miR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem. 390:19–30. 2014. View Article : Google Scholar : PubMed/NCBI
27	Wong CM, Wei L, Au SL, Fan DN, Zhou Y, Tsang FH, Law CT, Lee JM, He X, Shi J, et al: MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. Oncotarget. 6:13658–13670. 2015. View Article : Google Scholar : PubMed/NCBI
28	de-Freitas-Junior JC, Carvalho S, Dias AM, Oliveira P, Cabral J, Seruca R, Oliveira C, Morgado-Díaz JA, Reis CA and Pinho SS: Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin. PLoS One. 8:e815792013. View Article : Google Scholar : PubMed/NCBI
29	Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG, et al: DIAGRAM Consortium; MAGIC Investigators: The Lin28/let-7 axis regulates glucose metabolism. Cell. 147:81–94. 2011. View Article : Google Scholar : PubMed/NCBI
30	Cho MH, Park JH, Choi HJ, Park MK, Won HY, Park YJ, Lee CH, Oh SH, Song YS, Kim HS, et al: DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat Commun. 6:78212015. View Article : Google Scholar : PubMed/NCBI